Repligen (RGEN) Financial Analysis & Valuation | Quarter Chart
Repligen (RGEN)
RGENPrice: $137
Fair Value: 🔒
🔒score
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography r... more
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in b... more
Description
Shares
| Market Cap | $7.73B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Olivier Loeillot |
| IPO Date | 1986-04-29 | CAGR | 0.15% |
| Employees | 1,778 | Website | www.repligen.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.02% | Total Yield | 0.02% |
RGEN chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.90B | P/E Ratio | 76.11 |
| Forward P/E | 53.78 | PEG Ratio | 3.14 |
| P/S Ratio | 122.53 | P/B Ratio | 44.43 |
| P/CF Ratio | 715.7 | P/FCF Ratio | 899.79 |
| EPS | $1.8 | EPS Growth 1Y | — |
| EPS Growth 3Y | -69.49% | EPS Growth 5Y | -37.93% |
| Revenue Growth 1Y | 17.36% | Gross Margin | 0.5% |
| Operating Margin | 0.09% | Profit Margin | 0.07% |
| ROE | 0.02% | ROA | 0.02% |
| ROCE | 0.02% | Current Ratio | 9.2 |
| Quick Ratio | 7.78 | Cash Ratio | 4.62 |
| Debt/Equity | 0.33 | Interest Coverage | 1.49 |
| Altman Z Score | 6.56 | Piotroski Score | 6 |